Completed PHASE4 INTERVENTIONAL NCT00703898

Durability of Nevirapine-Based Antiretroviral Regimen

Durability of Stavudine, Lamivudine and Nevirapine Among Advanced HIV-1 Infected Patients With/Without Prior Co-Administration of Rifampicin: A 144-Week Prospective Study

Sponsor: Bamrasnaradura Infectious Diseases Institute

Conditions HIV Infections

Interventions nevirapine

Updated 5 times since 2017 Last updated: Jul 7, 2008 Started: Nov 30, 2004 Primary completion: Dec 31, 2009 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00703898, this PHASE4 trial focuses on HIV Infections and remains completed. Sponsored by Bamrasnaradura Infectious Diseases Institute, it has been updated 5 times since 2004, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bamrasnaradura Infectious Diseases Institute

Data source: Bamrasnaradura Infectious Diseases Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nonthaburi, Thailand